

APPLICANT (stamp or sticker acceptable) **PATIENT** NHI: **REFERRER** Reg No:
Reg No: First Names: First Names:
Name: Surname: Surname:
Address: DOB: Address:
..... Address:
.....
Fax Number: Fax Number:

Epoprostenol

Initial application — PAH dual therapy

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

☐	Patient has pulmonary arterial hypertension (PAH)																					
and	☐	PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications																				
and	☐	PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV																				
and	<table border="1"><tr><td>☐</td><td>PAH has been confirmed by right heart catheterisation</td></tr><tr><td>and</td><td>☐</td><td>A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</td></tr><tr><td>and</td><td>☐</td><td>A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</td></tr><tr><td>and</td><td>☐</td><td>A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)</td></tr><tr><td>and</td><td><table border="1"><tr><td>☐</td><td>PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †</td></tr><tr><td>or</td><td>☐</td><td>Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td>☐</td><td>Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table></td></tr></table>	☐	PAH has been confirmed by right heart catheterisation	and	☐	A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)	and	☐	A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg	and	☐	A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)	and	<table border="1"><tr><td>☐</td><td>PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †</td></tr><tr><td>or</td><td>☐</td><td>Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td>☐</td><td>Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	☐	PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †	or	☐	Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	or	☐	Patient has PAH other than idiopathic / heritable or drug-associated type
☐	PAH has been confirmed by right heart catheterisation																					
and	☐	A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)																				
and	☐	A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg																				
and	☐	A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)																				
and	<table border="1"><tr><td>☐</td><td>PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †</td></tr><tr><td>or</td><td>☐</td><td>Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td>☐</td><td>Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	☐	PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †	or	☐	Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	or	☐	Patient has PAH other than idiopathic / heritable or drug-associated type													
☐	PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †																					
or	☐	Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**																				
or	☐	Patient has PAH other than idiopathic / heritable or drug-associated type																				
or	☐	Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease																				
or	☐	Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures																				
and	<table border="1"><tr><td>☐</td><td>Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist</td></tr><tr><td>and</td><td>☐</td><td>Patient is presenting in NYHA/WHO functional class IV</td></tr><tr><td>and</td><td>☐</td><td>Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool</td></tr></table>	☐	Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist	and	☐	Patient is presenting in NYHA/WHO functional class IV	and	☐	Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool													
☐	Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist																					
and	☐	Patient is presenting in NYHA/WHO functional class IV																				
and	☐	Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool																				

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Epoprostenol - continued

Initial application — PAH triple therapy

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has pulmonary arterial hypertension (PAH)
and
☐ PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications
and
☐ PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV
and

☐ PAH has been confirmed by right heart catheterisation
and
☐ A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)
and
☐ A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
and
☐ A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)
and

☐ PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †
or
☐ Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**
or
☐ Patient has PAH other than idiopathic / heritable or drug-associated type

or
☐ Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease
or
☐ Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures

and
☐ Epoprostenol is to be used as PAH triple therapy
and

☐ Patient is on the lung transplant list
or
☐ Patient is presenting in NYHA/WHO functional class IV
or

☐ Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool
and
☐ Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario
- I confirm the above details are correct and that in signing this form I understand I may be audited.
- Signed: Date:
- Post application to Ministry of Health, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Epoprostenol - *continued*

Renewal

Current approval Number (if known):.....

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years.

Prerequisites(tick box where appropriate)

☐

Patient is continuing to derive benefit from epoprostenol treatment according to a validated PAH risk stratification tool**

Note: † The European Respiratory Journal Guidelines can be found here: [2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH](#)

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz